EMA Panel Backs Solriamfetol (Sunosi) for Narcolepsy, OSA

The dual-acting dopamine and norepinephrine reuptake inhibitor showed durable effects in reducing excessive sleepiness in patients with narcolepsy or obstructive sleep apnea (OSA).
International Approvals

Source link

Related posts

‘Superagers’ over 80 have the memory and brain connectivity of twenty-somethings


Message from the Editors to our Reviewers


Associated and predictive factors of quality of life in patients with temporal lobe epilepsy.


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World